• HBM Holdings secured China NMPA clearance to start clinical trials of HBM7575 (SKB575) for asthma.
• The long-acting bispecific antibody targets TSLP and a second undisclosed antigen.
• Asset is co-developed with Kelun-Biotech, which leads global development and commercialization under the collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245206), on July 15, 2026, and is solely responsible for the information contained therein.